Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children

Pediatric Infectious Disease Journal

Volumn 19, Issue 3, 2000, Pages 187-195

  Black, Steven ^a   Shinefield, Henry ^a   Fireman, Bruce ^a   Lewis, Edwin ^a   Ray, Paula ^a   Hansen, John R ^a   Elvin, Laura ^a   Ensor, Kathy M ^a   Hackell, Jill ^b   Siber, George ^b   Malinoski, Frank ^b   Madore, Dace ^b   Chang, Ih ^b   Kohberger, Robert ^b   Watson, Wendy ^b   Austrian, Robert ^c   Edwards, Kathy ^d   Aguilar, Janet ^e   Bartlett, Marissa ^e   Bergen, Randy ^e   Burman, Mel ^e   Dorfman, Steve ^e   Easter, Wayne ^e   Finkel, Annette ^e   Froehlich, Hervey ^e   Glauber, James ^e   Herz, Arnd ^e   Honeychurch, David ^e   Kleinrock, Robert ^e   Landaw, Irene ^e   Lavetter, Allan ^e   Le, Chinh ^e   McMurtry, Steve ^e   Morozumi, Pius ^e   Mullin, Pat ^e   Rehbein, Michael ^e   Rossin, Richard ^e   Soe, Garwin ^e   Takahashi, Irene ^e   Udkow, Gail ^e   Whitson, Robert ^e   more..

^a KAISER PERMANENTE   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e NONE

Author keywords

Efficacy; Heptavalent pneumococcal conjugate vaccine; Immunogenicity; Safety

Indexed keywords

MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; FEBRILE CONVULSION; FEVER; HUMAN; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; OTITIS MEDIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS INFECTION;

BACTERIAL VACCINES; CONSUMER PRODUCT SAFETY; DOUBLE-BLIND METHOD; HUMANS; INFANT; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; RISK FACTORS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 0034063425     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200003000-00003     Document Type: Article

References (24)

1. CDC. Progress toward elimination of Haemophilus influenzae type b among infants and children: United States, 1987-1993. MMWR 1994;43:144-8.
2. CDC. Drug resistant Streptococcus pneumoniae: Kentucky and Tennessee, 1993. MMWR 1994;43:23-5.
3. STAT EXACT Statistical Package. Cambridge, MA: Cytel Statistical Software, 1998.
4. Fleming, TR, Harrington DP. Counting processes and survival analysis. New York: Wiley, 1991.
5. SAS Institute Inc. SAS/STAT Software: changes and enhancements through release 6.12. Cary, NC: SAS Institute Inc., 1997:942.
6. Quataert SA, Kirch CS, Wiedl LJ, et al. Assignment of weight-based antibody units to a human anti-pneumococcal standard reference serum lot 89-S. Clin Diag Lab Immunol 1995;2:590-7.
7. Shinefield HR, Black S, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999;18: 757-63.
8. Froom J, Culpepper L, Grob P, et al. Diagnosis and antibiotic treatment of acute otitis media: report from International Primary Care Network. Br Med J 1990;300:582-6.
9. 197 in United States infants. Pediatrics 1998; 101:604-11.
10. Black S, Shinefield H. Progress toward effective pneumococcal vaccination in infancy. Contemp Pediatr 1998;Nov-(Suppl):12-17.
11. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994;331:337-42.
12. Zenni MK, Cheatham SH, Thompson JM, et al. Streptococcus pneumoniae colonization in the young child: association with otitis media and resistance to penicillin. J Pediatr 1995;127: 533-7.
13. Shurin PA, Rehmus JM, Johnson CE, et al. Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high risk children. J Pediatr 1993;123:801-10.
14. Rubin LG, Mardy GV, Pais L, Carlone G. Human anticapsular antibody concentration reuired for protection against experimental pneumococcal bacteremia [Abstract G-47]. In: Proceedings of the 35th Interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17 to 20, 1995. Washington, DC: American Society for Microbiology, 1995.
15. Saladino RA, Stack AM, Malley R, Thompson CM, Siver CR, Fleiser GO. Bacterial polysaccharide immune globulin (BPIG) protects infant rats with S. pneumoniae (SP) pneumonia from bacteremia, meningitis and death. Pediatr Res 1996;36:184A.
16. Siber GR. Methods for estimating serologic correlates of protection. Dev Biol Stand 1997;89:283-96.
17. Pelton PI. Otoscopy for the diagnosis of otitis media. Pediatr Infect Dis J 1998;17:540-3.
18. Bluestone CD, Klein JO. Otitis media in infants and children. 2nd ed. Philadelphia: Saunders, 1995.
19. Anttilla M, Eskola J, Ahman H, Kayhty H. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine 1999;17: 1970-7.
20. Eskola J. Efficacy of pneumococcal conjugate vaccine against otitis media [Late-Breaker Abstract]. Presented at the 39th Interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26 to 29, 1999.
21. Schappert SM. Office visits for otitis media: United States, 1975-90. CDC Advance Data 1992;214:1-20.
22. CDC. Ambulatory and impatient procedures in the United States, 1996. Series 13. Data from the National Health Care Survey, No. 139. PHS 99-1710, November, 1998.
23. Dagan R, Melamed R, Muallem M, et al. Reduction of a nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996;174:1271-8.
24. Dagan R, Muallem M, Leroy O, Yagupsky P. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J 1997;16:1060-4.